China issues healthcare big data rules, to establish platform for data sharing



The National Health Commission (NHC) released a set of rules in relation to medical and healthcare big data management standards that take immediate effect. The document can be seen to be providing clarity for hospitals, medical institutions, and other bodies that gather health and medical data regarding standards for collection, storage, and use.

Medical and healthcare big data is defined as all health-related data generated via disease prevention and health management activities. The rules are applied to all health administrative departments (including traditional Chinese medicine (TCM)) at the county level and above, medical and health institutions at all levels, as well as all other companies and individuals coming into contact with health-related data. The document sets out the key duties of the NHC as the health data standard-setting authority; and considerations and key standards for units gathering data in terms of safe storage, collection, mining, application, and transmission of data.

Among the clauses, the NHC has been tasked with establishing a working mechanism for the open sharing of health care big data in accordance with relevant provisions on open sharing of national information resources. This signals a new, open stance and commitment from the government to strengthen the sharing and exchange of health care data in China, via a coordinated reporting system and platform.
Reference:


Related news
Switzerland-based giant Novartis AG’s China unit signed a memorandum to form a strategic cooperation with Chinese internet major Tencent.
China’s National Health Commission (NHC) issued three separate trial measures setting out management measures for the fields of “online diagnosis and treatment”, “online hospitals”, and “online telemedicine”.
The National Health Commission (NHC) held a press conference during which further details of the update to the National Essential Drug List (NEDL) were released.
China’s State Council released a notification relating to medical and healthcare system reforms planned for the second half of 2018.
China’s National Health Commission (NHC), State Administration for Market Regulation (SAMR), State Medical Insurance Administration (SMIA) and another 6 bureaus jointly released a notification on “Correcting Misconduct During Medical Purchasing and Medical Services”, indicating closer scrutiny in a number of areas.
Recent news
(本文翻译自GBI 英文版杂志CPB Review 127期cover story,原文作者:Robert Mctiernan,翻译:Danni Yang。
  • 1537342679813
  • China
O INPI (Instituto Nacional de Propriedade Industrial) anunciou nesta terça-feira (18) que concedeu à farmacêutica americana Gilead a patente sobre o sofosbuvir, medicamento que cura a hepatite C em mais de 95% dos casos. Com isso, a Fiocruz-Farmanguinhos fica impedida de produzir o sofosbuvir genérico, que já estava registrado pela Anvisa e geraria uma economia de R$ 1 bilhão parao Ministério da Saúde. Países como Egito, Argentina e China não concederam a patente à Gilead e produzem os genéricos.Outros países, como o Chile, estudam quebrar a patente (licenciamento compulsório) do sofosbuvir. Em nota, o INPI, vinculado ao Ministério da Indústria e Comércio,afirma ter deferido a patente para uma molécula (intermediária para a síntese do sofosbuvir), relativa a duas reivindicações (que especificam o objeto da patente) feitas pela empresa Gilead.
阿达木单抗(Adalimumab)系在中国仓鼠卵巢细胞中表达的重组全人源化肿瘤坏死因子α(Tumor Necrosis Factor, TNFα)单克隆抗体注射液,由美国雅培公司研发上市,商品名为:修美乐(Humira®)。
Bagsværd, Denmark, 18 September 2018 ­-Novo Nordisk today announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious chronic diseases.
Denmark-based diabetes giantNovo Nordiskis moving to recalibrate the direction of its global research and development (R&D) activities, cutting back on in-house R&D operations in Denmark and China in order to introduce a more agile model.
-惠及亿万患者,诺和诺德承诺改变中国糖尿病 天津2018年9月18日电 /美通社/ -- 2018年9月18日至20日,世界经济论坛第十二届新领军者年会(2018夏季达沃斯论坛)在天津梅江会展中心隆重举行。
Si usted es una persona que presenta síntomas de fiebre, dolor de cabeza e hinchazón de las mejillas y mandíbula, debe prestar atención. El lunes la secretaría de Salud declaró una alerta en el país ante un inusitado incremento de casos de paperas (parotiditis, en términos médicos). Según las autoridades, un promedio de 18 personas son atendidas a diario en los centros asistenciales del país producto de la enfermedad que se origina en la inflamación de las glándulas salivales y que se propaga por el aire, de persona a persona, al toser, estornudar o simplemente al hablar. De acuerdo a los reportes, hasta la última semana de agosto, en los diferentes hospitales del país habían sido atendidas más de 5,000 personas a raíz de este padecimiento. Esta cantidad desproporcionada de casos ha encendido las alertas en virtud de que el año anterior apenas se registraron 138 pacientes a nivel nacional, es decir que hay un incremento superior a los 4,800 casos. Ida Berenice Molina, coordinadora del Programa Ampliado de Inmunizaciones (PAI), manifestó que “en promedio se presentaban anualmente 138 casos de parotiditis hasta el año 2017, pero en este añ
Analytics Snapshot


Actionable intelligence at your fingertips.